Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ERRATUM.

Enrico Mini1, Ida Landini1, Laura Lucarini2

  • 1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Oncology Research
|March 9, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

British journal of haematology·2026
Same author

Corrigendum to "The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics" J Inorg Biochem 2013 Jan:118:94-9. doi:10.1016/j.jinorgbio.2012.10.003. Epub 2012 Oct 14.

Journal of inorganic biochemistry·2026
Same author

Corticosteroid-dependent increased expression of CGRP and its receptor subunits within the rodent trigeminal ganglion does not prompt cephalic allodynia.

Cephalalgia : an international journal of headache·2025
Same author

Ulcerative colitis and colorectal cancer: Pathogenic insights and precision strategies for prevention and treatment.

World journal of gastrointestinal oncology·2025
Same author

Cancer cell death induced by the NAD antimetabolite Vacor discloses the antitumor potential of SARM1.

FEBS letters·2025
Same author

Effects of reduced extracellular sodium on proliferation and invasive activity of renal cell carcinoma cell lines.

Scientific reports·2025
Same journal

New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.

Oncology research·2026
Same journal

Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.

Oncology research·2026
Same journal

Exploring the Role of CD44 in the Progression and Invasion of Chondrosarcoma.

Oncology research·2026
Same journal

Retraction: Long Noncoding RNA Taurine-Upregulated Gene 1 Promotes Cell Proliferation and Invasion in Gastric Cancer via Negatively Modulating miRNA-145-5p.

Oncology research·2026
Same journal

Retraction: Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.

Oncology research·2026
Same journal

Targeting Dynamin-Related Protein 1 and Glucose Metabolism Reverses Acquired Resistance to Sorafenib in Liver Cancer.

Oncology research·2026
See all related articles

A novel poly(ADP-ribose) polymerase inhibitor (PARPI), HYDAMTIQ, effectively inhibits tumor cell growth, particularly in cells with DNA repair defects. It shows synergistic effects with 5-fluorouracil in certain cancer types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase (PARP) enzymes are crucial for cellular processes, including DNA damage repair and genomic stability.
  • PARP inhibitors (PARPIs) exploit synthetic lethality, selectively killing cancer cells with DNA repair deficiencies.
  • PARP inhibition can enhance the efficacy of chemotherapy agents like 5-fluorouracil by increasing DNA damage.

Purpose of the Study:

  • To evaluate the growth inhibitory effects of a novel PARPI, HYDAMTIQ, on human tumor cell lines.
  • To assess HYDAMTIQ's activity in relation to DNA damage response pathways (BRCA mutation, microsatellite status, ATM expression) and 5-fluorouracil sensitivity.
  • To investigate the combined effects of HYDAMTIQ and 5-fluorouracil on tumor cell growth.

Main Methods:

Related Experiment Videos

  • Testing HYDAMTIQ's antiproliferative effects on various human tumor cell lines with differing DNA repair pathway statuses.
  • Analyzing the impact of HYDAMTIQ based on BRCA mutational status, microsatellite instability (MS) status, and ATM expression levels.
  • Evaluating the synergistic or antagonistic effects of combining HYDAMTIQ with 5-fluorouracil.

Main Results:

  • HYDAMTIQ demonstrated potent growth inhibition in a BRCA2-mutant cell line (CAPAN-1) compared to wild-type cells.
  • No significant differences in HYDAMTIQ sensitivity were observed based on microsatellite or MRE11 mutational status.
  • HYDAMTIQ showed greater antiproliferative effects in cells with low ATM expression (SW620) versus high ATM expression (H630).
  • The combination of HYDAMTIQ and 5-fluorouracil was synergistic in SW620 cells and antagonistic in H630 cells.

Conclusions:

  • The novel PARPI HYDAMTIQ effectively inhibits the growth of human tumor cells with compromised DNA damage response pathways.
  • HYDAMTIQ exhibits potential for synergistic cytotoxicity when combined with 5-fluorouracil in specific cellular contexts.
  • These findings support further development of HYDAMTIQ as a targeted cancer therapy, illustrating synthetic lethality principles.